An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
Clinical trial NCT04659174 · COMPLETED
Trial details
- NCT number
- NCT04659174
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-01
- Primary completion
- 2023-10-03
- Enrollment
- 152
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.